 SAN FRANCISCO, June 10, 2021 PRNewswire -- Schubert Jonckheer Kolbe LLP is investigating potential derivative claims on behalf of shareholders of CytoDyn Inc. OTC: CYDY relating to possible false statements to investors and insider trading by two officers and a director. In or around March 2020, in the early stages of the COVID-19 pandemic, CytoDyn attempted to pivot its existing drug candidate, leronlimab, which was originally developed for the treatment of HIV, to be used instead as a treatment for severe cases of COVID-19. 